95 (d, J = 8.4 Hz, 2H, H-2′ & H-6′), 7.82 (d, J = 8.4 Hz, 2H, H-3′ & H-5′), 7.52–7.47 (m, 5H, H-2′’ to H-6′’), 7.41 (d, J = 2.0 Hz, 1H, H-6), 6.90 (dd, J = 8.4, 2.0 Hz, 1H, H-4), 6.64 (d, J = 8.4 Hz, 1H, H-3), 3.49 (s, 2H, H-7′’), 3.40 (s, 3H, CH3O-2), 2.55 (s, 3H, CH3CO); EI-MS: m/z 431 [M + 2]+, 429 [M]+, 414 [M-CH3]+, 398 [M-OCH3]+, 365 [M-SO2]+, 183 [C8H7OSO2]+, 156 [C7H7ClNO]+. Light grey amorphous solid; Yield: 74%; M.P. 112–114 °C; Molecular formula: C24H20ClNO3S; Molecular weight: 437; IR (KBr, ѵmax/cm−1): 3087 (Ar C H stretching), 1618
(Ar C C stretching), 1366 (S O stretching); 1H NMR (400 MHz, CDCl3, ppm): δ 8.32 Epacadostat (brd s, 1H, H-7′), 7.94 (d, J = 8.0 Hz, 1H, H-4′), 7.83 (d, J = 8.4 Hz, 1H, H-3′), 7.82 (d, J = 2.4 Hz, 1H, H-8′), 7.71 (dd, J = 8.4, 2.0 Hz, 1H, H-2′),
7.58 (ddd, J = 9.6, 1.2 Hz, 1H, H-6′), 7.54 (ddd, J = 9.6, 2.4 Hz, 1H, H-5′), 7.25–7.21 (m, 5H, H-2′’ to H-6′’), 7.10 (brd s, 1H, H-6), 6.95 (dd, J = 8.4, 2.4 Hz, 1H, H-4), 6.55 (d, J = 8.4 Hz, 1H, H-3), 3.39 (s, 2H, H-7′’), Regorafenib 3.32 (s, 3H, CH3O-2); EI-MS: m/z 439 [M + 2]+, 437 [M]+, 422 [M-CH3]+, 406 [M-OCH3]+, 373 [M-SO2]+, 191 [C10H7SO2]+, 156 [C7H7ClNO]+. The antibacterial activity was processed using a reported method.8 and 9 Four Gram-negative and two Gram-positive bacteria were maintained on stock culture agar medium. The total volume of each well was 200 μL with 20 μg of the test samples diluted by solvents and 180 μL of overnight maintained fresh bacterial culture after suitable dilution with fresh nutrient broth. The initial absorbance was maintained between 0.12 and 0.19 at 540 nm and the incubation was processed at 37 °C for 16–24 h with lid on the microplate. The absorbance was observed before and after incubation at 540 nm using microplate reader; and
about the difference was an indicant of bacterial growth. The percent inhibition was calculated using the formula, Inhibition(%)=X−YX×100where X is absorbance in control with bacterial culture and Y is absorbance in test sample. Ciprofloxacin was used as reference standard. Minimum inhibitory concentration (MIC) was also computed with suitable dilutions (5–30 μg/well) and results were calculated using EZ-Fit5 Perrella Scientific Inc. Amherst USA software. Due to high curiosity for the new inhibitors compounds having much potential against the different microbes, the attempt was made to contribute in this regard. Our objective was to synthesize some new N-(un)substituted aryl sulfonamides and to find out their antibacterial activities. The N-(5-chloro-2-methoxyphenyl)-aryl sulfonamides (3a–e) and N-benzyl/ethyl substituted N-(5-chloro-2-methoxyphenyl)-aryl sulfonamides (6a–e & 7a–e) were synthesized according to the protocol sketched in Scheme 1, in excellent yields having good antibacterial activities.